Cargando…

Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant

The impact of pre‐transplant anti‐severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vaccine in 20 recipients of allogeneic hematopoietic stem cell transplantation (Allo‐HSCT) and/or their donors is reported here, showing that the persistence of anti‐SARS‐CoV‐2 antibodies can be detected i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jullien, Maxime, Coste‐Burel, Marianne, Clemenceau, Beatrice, Letailleur, Valentin, Guillaume, Thierry, Peterlin, Pierre, Garnier, Alice, Bourgeois, Amandine Le, Imbert, Berthe‐Marie, Ollier, Jocelyn, Grain, Audrey, Touzeau, Cyrille, Moreau, Philippe, Béné, Marie C, Vié, Henri, Chevallier, Patrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924852/ https://www.ncbi.nlm.nih.gov/pubmed/35313664 http://dx.doi.org/10.1002/jha2.398

Ejemplares similares

Incidence and Severity of COVID-19 Infections in a Cohort of 211 Allotransplanted Patients after One or Two Boosters during the Omicron Wave in France
por: Letailleur, Valentin, et al.
Publicado: (2022)

SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine
por: Clémenceau, Béatrice, et al.
Publicado: (2022)

Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
por: Clémenceau, Béatrice, et al.
Publicado: (2022)

Post‐transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced‐intensity conditioning allotransplant
por: Bourgeois, Amandine Le, et al.
Publicado: (2023)

Sars-Cov-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Transplant Recipients
por: Clemenceau, Beatrice, et al.
Publicado: (2022)

Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine
por: Clemenceau, Beatrice, et al.
Publicado: (2021)

Assessment of COVID-19 Incidence and Severity Among Recipients of Allogenic Stem Cell Transplant After 1 or 2 mRNA Booster Doses During the Omicron Wave in France
por: Letailleur, Valentin, et al.
Publicado: (2022)

Efficacy of Anti-Sars-Cov-2 mRNA Vaccines in Adults with Severe Acquired Aplastic Anemia with or without Allograft
por: Garnier, Alice, et al.
Publicado: (2022)

Efficacy of anti‐severe acute respiratory syndrome coronavirus 2 mRNA vaccines in adults with severe acquired aplastic anemia with or without allogeneic hematopoietic stem cell transplantation
por: Garnier, Alice, et al.
Publicado: (2022)

Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients
por: Chevallier, Patrice, et al.
Publicado: (2021)

B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Jullien, Maxime, et al.
Publicado: (2022)

Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients
por: Le Bourgeois, Amandine, et al.
Publicado: (2021)

Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy
por: Gastinne, Thomas, et al.
Publicado: (2021)

Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Jullien, Maxime, et al.
Publicado: (2021)

Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Le Bourgeois, Amandine, et al.
Publicado: (2021)

Peripheral levels of monocytic myeloid‐derived suppressive cells before and after first induction predict relapse and survivals in AML patients
por: Peterlin, Pierre, et al.
Publicado: (2022)

Assessment of monocytic‐myeloid‐derived suppressive cells (M‐MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients
por: Peterlin, Pierre, et al.
Publicado: (2023)

Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation
por: Retière, Christelle, et al.
Publicado: (2018)

Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft
por: Jullien, Maxime, et al.
Publicado: (2020)

Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells
por: Grain, Audrey, et al.
Publicado: (2023)

Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies
por: Chevallier, Patrice, et al.
Publicado: (2018)

P534: FIRST-IN-HUMAN TRIAL OF TOCILIZUMAB IN COMBINATION WITH A STANDARD INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS: THE PHASE 1 TOCILAM STUDY.
por: Peterlin, Pierre, et al.
Publicado: (2023)

Tocilizumab in combination with a standard induction chemotherapy in acute myeloid leukaemia patients (TOCILAM study): a single-centre, single-arm, phase 1 trial
por: Peterlin, Pierre, et al.
Publicado: (2023)

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases
por: Peterlin, Pierre, et al.
Publicado: (2018)

A new cytokine‐based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia
por: Peterlin, Pierre, et al.
Publicado: (2020)

Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post‐transplant cyclophosphamide
por: Jullien, Maxime, et al.
Publicado: (2021)

An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains
por: Andre-Garnier, Elisabeth, et al.
Publicado: (2017)

Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response
por: Makanga, Dhon Roméo, et al.
Publicado: (2021)

Genetic and Molecular Basis of Heterogeneous NK Cell Responses against Acute Leukemia
por: Makanga, Dhon Roméo, et al.
Publicado: (2020)

Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
por: Jullien, Maxime, et al.
Publicado: (2020)

Medullary allotransplant in acute myeloblastic leukemia in a child
por: Buga Corbu, V, et al.
Publicado: (2014)

Vascularised composite allotransplants: Transplant of upper extremities and face
por: Iyer, Subramania
Publicado: (2015)

Effect of Immunosuppression on the Hybrid Skeleton of Vascularized Composite Allotransplants?
por: Kerr, Katelyn, et al.
Publicado: (2022)

Optimal FSH usage in revascularization of allotransplanted ovarian tissue in mice
por: Ma, Wen-Zhi, et al.
Publicado: (2017)

A Flow Dynamic Rationale for Accelerated Vascularized Composite Allotransplant Rejection
por: Robbins, Nicholas L., et al.
Publicado: (2019)

Engraftment of Allotransplanted Tumor Cells in Adult rag2 Mutant Xenopus tropicalis
por: Tulkens, Dieter, et al.
Publicado: (2022)

SAT239 Deceased Donor Parathyroid Allotransplant For Sever Refractory Iatrogenic Hypoparathyroidism
por: Devon, Karen M, et al.
Publicado: (2023)

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective
por: Trudel, Sabrina, et al.
Publicado: (2019)

Post-SARS-CoV-2 vaccination specific antibody decrease : Let's get the half-full glass perspective
por: Béné, Marie C, et al.
Publicado: (2021)

Allotransplanted Neurons Used to Repair Peripheral Nerve Injury Do Not Elicit Overt Immunogenicity
por: Liu, Weimin, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_gpgtc0ptuvup5l8m079s709n64